메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy

HONG KONG, Jan. 5, 2026 -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to initiate Phase 1/2 CLARITY trial activities for its lead in vivo genome-editing program GEB-101 for TGFBI corneal dystrophy. The Phase 1/2 CLARITY trial will collect initial data on the safety, tolerability and efficacy of GEB-101 in corneal dystrophy patients with TGFBI
- 김갑성 기자
- 2026-01-05 12:07
GMA Capital Partners Joins Responsible Investment Association Australasia

SINGAPORE, Jan. 5, 2026 -- GMA Capital Partners has been approved as a member of the Responsible Investment Association Australasia (RIAA), reflecting the firm's continued focus on responsible capital deployment and engagement with established sustainable investment frameworks across the Asia-Pacific region. Headquartered in Singapore, GMA Capital Partners is a principal investment firm focused on long-term investments, structured capital solutions, and cross-border partnerships in real-economy sectors, including infrastructure, energy transition, logistics, and strategic industrial ma
- 황정호 기자
- 2026-01-05 11:00
C&R Research, the 'K-Clinical Hub', Strengthens Partnerships in Indonesia

[ 메디채널 김갑성 기자 ] Accelerating Indonesia Collaboration through Global Clinical Capabilities SEOUL, South Korea, Jan. 5, 2026 -- C&R Research, founded in 1997 as Korea's first full-service Contract Research Organization (CRO), has played a pivotal role in advancing the Korean clinical trial industry and supporting the global expansion of Korean clinical research. With expertise across next-generation modalities, C&R Research has established itself as a key partner in global drug development. Leveraging its global subsidiaries and international network, C&R Research is
- 김갑성 기자
- 2026-01-05 10:00
Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes

-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 in participants with diabetes. Enrollment is expected to begin in the first quarter of 2026.-ASC30 demonstrated placebo-adjusted weight loss of 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or overweight, with better gastrointestinal tolerability. No hepatic safety signal was observed. HONG KONG, Jan. 5, 2026 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announc
- 김갑성 기자
- 2026-01-05 08:10
CTA: Despite Tariffs and Economic Headwinds, U.S. Consumer Tech Revenue to Hit $565 Billion in 2026

LAS VEGAS, Jan. 5, 2026 -- As tariff pressures and economic uncertainty impact the business landscape, the Consumer Technology Association (CTA)® today is releasing its U.S. Consumer Technology Industry Forecast showing the industry is projected to reach $565 billion in revenue in 2026, growing 3.7% year over year. The forecast is being unveiled during CTA's Tech Trends to Watch event during Media Days at CES® 2026, where industry leaders are gathering to discuss the latest innovations and assess the year ahead. The outlook underscores the industry's resilience at a piv
- 황정호 기자
- 2026-01-05 07:40
Babies Bliss Establishes a New Standard for Fertility Wellness in Singapore with a Whole-Person, Cycle-Aware Model

Singapore-based Fertility Wellness House positions complementary care as long-term support alongside IVF and assisted fertility treatments SINGAPORE, Jan. 5, 2026 -- Babies Bliss, a leading fertility wellness house in Singapore, is redefining how fertility journeys are supported through a whole-person, cycle-aware fertility wellness model designed to complement medical fertility treatments such as IUI and IVF. As more women and couples navigate prolonged fertility journeys, IVF fatigue, and the emotional strain of repeated treatment cycles, demand is rising for non-medical, supp
- 김갑성 기자
- 2026-01-05 07:00
To See 5,000 Years of China: Visit Hangzhou -- A Global Welcome Awaits

HANGZHOU, China, Jan. 4, 2026 -- Known for centuries as "heaven on earth" in Chinese lore, Hangzhou stands as a living window into China's profound civilization spanning over five millennia. Today, Hangzhou Municipal Bureau of Culture, Radio, Television and Tourism invites global visitors to explore its unparalleled heritage and modern hospitality. To enhance the shopping experience for international guests, Hangzhou has fully implemented and optimized its "Tax Refund for Tourists" (TRT) policy. Eligible overseas tourists can receive a refund on the Value-Ad
- 김장윤(JASON KIM) 기자
- 2026-01-04 15:56
Sports and Tourism Merge in Sanya as 2025 Marathon Wraps Up Along Scenic Coast

The race reflects Hainan's broader effort to link international sporting events with economic development and global engagement SANYA, China, Jan. 4, 2026 -- The 7th Hainan (Sanya) Marathon wrapped up on Sunday, attracting 14,000 participants from 20 countries and regions. Held under the theme "Run Past Your Limits. Straight to the Sea," the event combined tropical coastal scenery with competitive racing through diverse race formats, enhanced services, and digital innovation. After a grueling race, China's Yang Yuan won the women's full marathon in 2:50:11, while Zhao Guohu c
- 황정호 기자
- 2026-01-04 15:52
Daingt Co., Ltd. Launches New Gim Products Based on Raw Material Data, Expanding Its Quality-Focused Lineup

SEOUL, South Korea, Jan. 4, 2026 -- Daingt Co., Ltd. announced the launch of new gim (seaweed) products developed based on its accumulated production experience and raw material data. The newly introduced products were developed by actively leveraging Daingt's extensive database of graded raw materials and long-standing manufacturing know-how. The company analyzed preferred textures, aromas, and thicknesses across different consumer segments and distribution channels, then selected suitable raw materials to reflect these preferences in each product. Daingt also sought to differe
- 김갑성 기자
- 2026-01-04 08:00
NYSE Content Advisory: Pre-Market update + 2026 Trading Begins after the S&P 500's Strong 2025

NEW YORK, Jan. 2, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market update + 2026 Trading Begins after the S&P 500’s Strong 2025 Kristen Scholer delivers the pre-market update on January 2nd Tech stocks, especially AI names, are lifting the S&P 500 early in the first trading session of the year. Precious metals are also higher after silver and gold posted big gains in
- 황정호 기자
- 2026-01-02 21:55

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-05_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 05일 21시 40분